SEC Form 4 · accession 0001493152-26-028713
MIRA PHARMACEUTICALS, INC. · MIRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward Clouston MacPherson
Director
Period of report
Jun 12, 2026
Accepted (ET)
Jun 15, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001904286
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3,F1,F2 | $0.94 | Jun 12, 2026 | A | 50,000 | A | — | Jun 12, 2036 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.
- F2The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.
- F3Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.